{"filings":[{"id":77722,"accession_number":"0001193125-26-222818","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2026-05-14T11:36:49+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q1 2026 net loss $23.3M; MICVO data on track for mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.3M ($0.37/share) vs $21.2M ($0.35/share) YoY; R&D expenses rose to $20.0M from $17.0M.","Cash and equivalents $42.5M; expected runway into Q4 2026.","MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC (dose cap patients) on track for mid-2026.","MICVO + pembrolizumab Phase 1/2 combination dose escalation data in 1L R/M HNSCC expected 2H 2026.","Appointed Nelson Azoulay as Chief Business Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95393,"accession_number":"0001193125-26-193940","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K/A","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pyxis Oncology enters CEO separation agreement: 18-mo salary, equity acceleration, board resignation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation Agreement with former CEO Lara Sullivan became binding April 29, 2026; she resigned from Board same day.","Dr. Sullivan will receive current salary for 18 months and health coverage for up to 12 months.","All unvested RSUs and stock options accelerated; option exercise period extended to December 31, 2030.","One-year post-separation non-solicitation and mutual non-disparagement covenants apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108455,"accession_number":"0001193125-26-118525","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology completes MICVO enrollment, reports FY2025 net loss of $79.6M, names Interim CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed target enrollment (n~40) for MICVO Phase 1 monotherapy dose expansion in 2L+ R/M HNSCC in Q1 2026.","Updated MICVO monotherapy data expected mid-2026; combination data with KEYTRUDA expected 2H26.","Appointed Thomas Civik as Interim CEO; added SVPs of Global Clinical Ops, IR/Capital Markets, and Global Program Leader.","Cash and investments $68.3M at Dec 31, 2025; expected cash runway into Q4 2026.","FY2025 net loss $79.6M ($1.28/diluted) vs $77.3M ($1.32) in 2024; revenue $13.9M from royalty sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108454,"accession_number":"0001193125-26-041169","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology CEO Dr. Lara Sullivan steps down; board member Tom Civik appointed interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective February 2, 2026, Dr. Lara Sullivan stepped down as President, CEO, and CMO of Pyxis Oncology.","Board appointed Thomas Civik, a current director, as Interim CEO; base salary $710K, target bonus 60%.","Civik receives initial option grant (1.1% of shares) vesting monthly over 12 months, plus top-up (0.4%) upon successful transaction.","Board launched search for permanent CEO; Civik previously led Five Prime through its $1.9B acquisition by Amgen.","Lead program MICVO continues Phase 1/2 trials for head and neck squamous cell carcinoma; clinical operations unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124888,"accession_number":"0001193125-25-323704","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pyxis Oncology MICVO Phase 1 shows 46% ORR monotherapy, 71% ORR with Keytruda in HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MICVO monotherapy at 5.4 mg/kg: 46% confirmed ORR (6/13), 92% DCR in 2L+ R/M HNSCC; no Grade 4/5 TRAEs.","MICVO + Keytruda (3.6/4.4 mg/kg): 71% confirmed ORR (5/7), 100% DCR in 1L/2L+ HNSCC; no TRAE discontinuations.","Sold Enzeshu royalty rights for $11M one-time cash; cash runway extends into Q4 2026.","Monotherapy update expected mid-2026; combo update in 2H26; FDA alignment on pivotal study design obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124887,"accession_number":"0001193125-25-261689","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q3 net loss $22.0M; cash $77.7M, runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $22.0M ($0.35/share) for Q3 2025, vs $21.2M loss in Q3 2024.","Cash and equivalents $77.7M; expected to fund operations into H2 2026.","R&D expenses $17.8M; increase in MICVO costs offset by pause of PYX-106 program.","Preliminary Phase 1 data for micvotabart pelidotin (MICVO) in HNSCC expected in Q4 2025.","Translational data presented at ESMO and AACR-NCI-EORTC on MICVO's three mechanisms of action."],"consensus_eps_estimate":-0.3453,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":2820000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141594,"accession_number":"0000950170-25-108898","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q2 2025 net loss $18.4M, cash $90.4M; MICVO data milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $2.8M from milestone payment for suvemcitug approval in China, compared to $0 in Q2 2024.","Net loss $18.4M ($0.30 per share) vs $17.3M ($0.29) in prior year; adjusted loss $15.3M.","Cash, cash equivalents and short-term investments $90.4M; runway into H2 2026.","Preliminary MICVO monotherapy data in 2L/3L HNSCC expected H2 2025; combination with pembrolizumab data also H2 2025.","R&D expenses rose to $17.1M, driven by increased MICVO manufacturing and trial costs."],"consensus_eps_estimate":-0.3587,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":2820000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141593,"accession_number":"0000950170-25-101618","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology confirms HNSCC enrollment guidance for Phase 1 MICVO trial after ClinicalTrials.gov revision","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Revised ClinicalTrials.gov entry for MICVO (PYX-201) Phase 1 monotherapy trial reflects maximum patient enrollment per protocol.","Company reaffirms prior HNSCC patient enrollment estimates for Part 2 dose expansion as disclosed in May 15, 2025 10-Q.","No change to trial design or guidance; revision is administrative and consistent with industry practice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141592,"accession_number":"0000950170-25-093456","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pyxis Oncology CFO/COO Pamela Connealy retires; Jitendra Wadhane appointed PFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pamela Connealy, CFO and COO, retired from Pyxis Oncology effective July 1, 2025; not due to any disagreement.","Jitendra Wadhane, current SVP Finance and CAO, appointed Principal Financial Officer effective same date.","Wadhane continues as Principal Accounting Officer; no additional compensation for PFO role.","Connealy eligible for severance benefits per her Amended and Restated Employment Agreement (Nov 2022)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159445,"accession_number":"0000950170-25-087907","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pyxis Oncology annual meeting elects three directors, ratifies EY auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Dr. Santhosh Palani, Darren Cline, and Dr. Rachel Humphrey as Class I directors until 2028.","Palani received 22,056,449 For, 7,314,363 Withheld; Cline: 22,028,914 For, 7,341,898 Withheld; Humphrey: 21,357,102 For, 8,013,710 Withheld.","Ratified Ernst & Young as independent auditor for FY2025: 43,733,259 For, 233,563 Against, 29,628 Abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159444,"accession_number":"0000950170-25-071992","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology Q1 net loss $21.2M ($0.35); cash $106.9M; MICVO data on track for H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.2M ($0.35/share) vs $3.3M ($0.06) in Q1 2024; prior year included $16.1M Novartis settlement revenue.","Cash and investments $106.9M as of March 31, 2025; expected runway into second half of 2026.","R&D expenses rose to $17.0M from $13.0M, driven by increased clinical and manufacturing costs for MICVO.","On track to report Phase 1 monotherapy data for MICVO in HNSCC in H2 2025 and combination with pembrolizumab in H2 2025.","Preclinical data confirm three-pronged mechanism of MICVO (direct killing, bystander effect, immunogenic cell death)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177839,"accession_number":"0000950170-25-043491","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pyxis Oncology posts updated investor presentation; no specific new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation dated March 24, 2025, posted on company IR website.","Presentation slide deck title references 'Building a Differentiated ADC Company'.","No financial results, pipeline data, or strategic updates provided in the filing.","Filing does not include any earnings, guidance, or material business developments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177838,"accession_number":"0000950170-25-040767","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology reports FY2024 net loss $77.3M; MICVO 50% ORR in HNSCC; workforce cut 20%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 net loss $77.3M ($1.32 per share) vs $73.8M ($1.85) in 2023; cash $128.4M into 2H26.","MICVO (formerly PYX-201) achieved 50% confirmed ORR by RECIST 1.1 in R/M HNSCC Phase 1; Fast Track designation received.","Initiated MICVO monotherapy expansion cohorts and a Phase 1/2 combo trial with Merck's KEYTRUDA; data expected 2H25/1H26.","Workforce reduced ~20% primarily in G&A and preclinical; CMO Ken Kobayashi steps down; CEO Lara Sullivan to also serve as CMO.","Suspended PYX-106 development; recorded $21M non-cash impairment on PYX-107 IPR&D intangible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177837,"accession_number":"0000950170-25-027330","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology receives FDA Fast Track for PYX-201 in head and neck cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation to PYX-201 for recurrent/metastatic HNSCC after prior chemo and anti-PD-(L)1.","PYX-201 is a first-in-concept ADC targeting Extradomain-B Fibronectin in the tumor extracellular matrix.","CEO Lara Sullivan called the designation a significant milestone and said trial recruitment is ongoing.","Fast Track aims to speed development and review for serious conditions with unmet medical need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177836,"accession_number":"0000950170-25-012846","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology initiates combo trial PYX-201 + Keytruda and monotherapy expansion in HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/2 combo trial PYX-201-102 with Keytruda (pembrolizumab) in multiple solid tumors including R/M HNSCC, HR+/HER2- BC, TNBC; first dosing on track for Q1 2025.","Part 2 monotherapy expansion cohorts of Phase 1 PYX-201-101 began enrolling for 2L/3L R/M HNSCC patients who received prior platinum and PD-1 or EGFR and PD-1 inhibitors.","PYX-201 is a first-in-concept ADC targeting Extradomain-B Fibronectin (EDB+FN) in tumor extracellular matrix, designed to induce immunogenic cell death.","Combo trial is part of a Clinical Trial Collaboration Agreement with Merck (MRK)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194543,"accession_number":"0000950170-24-138563","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology prioritizes PYX-201 after 50% ORR in HNSCC; suspends PYX-106","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed 50% ORR and 100% DCR in 6 heavily pretreated HNSCC patients in Phase 1 of PYX-201.","Across 6 solid tumor types (n=31), PYX-201 achieved 26% ORR with dose-dependent responses in taxane-pretreated patients.","PYX-106 program suspended; Phase 1 monotherapy enrolled 45 patients, was safe and well-tolerated.","Current cash position expected to fund PYX-201 monotherapy and combination trials into 2H 2026.","Monotherapy and pembrolizumab combination trials for PYX-201 expected to start dosing in early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194542,"accession_number":"0000950170-24-129238","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PYX-201 achieves 50% ORR in HNSCC; Merck collaboration for KEYTRUDA combo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PYX-201 achieved 50% confirmed ORR by RECIST 1.1 (1 CR, 2 PR) and 100% DCR in 6 heavily pretreated HNSCC patients.","Overall 26% ORR across six solid tumor types (n=31) with dose-dependent responses; ovarian, NSCLC, breast, sarcoma also showed shrinkage.","Entered Clinical Trial Collaboration with Merck to evaluate PYX-201 + KEYTRUDA in HNSCC, HR+/HER2- breast, TNBC, sarcoma; dosing starts Q1 2025.","PYX-201 generally well-tolerated; low incidence of Grade 3/4 TRAEs; favorable PK profile with increased stability.","Multiple Phase 1 expansion studies and combo studies to begin Q1 2025 with data readouts expected throughout 2025 and 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194541,"accession_number":"0000950170-24-124581","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology reports Q3 2024 net loss of $21.2M; cash runway into 2H 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents of $146.3M as of Sept 30, 2024; expected to fund operations into 2H 2026.","Net loss of $21.2M ($0.35/share) vs $23.0M ($0.56/share) in Q3 2023.","R&D expenses rose to $17.7M from $14.7M due to increased clinical trial costs for PYX-201 and PYX-106.","Preliminary Phase 1 data for lead ADC PYX-201 to be presented at investor event on Nov 20, 2024; 80 patients dosed.","Phase 1 data for PYX-106 (Siglec-15 antibody) expected by year-end 2024; 45 patients dosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194540,"accession_number":"0000950170-24-116698","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Pyxis Oncology shareholders approve 5.5M share increase in equity plan at special meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders voted 23,234,250 to 12,829,636 to approve amendment to 2021 Equity and Incentive Plan adding 5,500,000 shares.","Proposal to adjourn if needed passed but was unnecessary; quorum of 36,189,305 shares present.","59,422,945 shares outstanding; special meeting held virtually on October 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210875,"accession_number":"0000950170-24-097054","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q2 net loss $17.3M; cash $157.2M funds into 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.3M ($0.29/shr) vs $15.9M ($0.41/shr) in Q2 2023; R&D spend $13.9M.","Cash, equivalents and short-term investments $157.2M as of June 30, 2024; runway into 2H 2026.","PYX-201 Phase 1: 72 subjects dosed; preliminary data (efficacy, safety, PK) expected fall 2024.","PYX-106 Phase 1: 33 subjects dosed; preliminary data (PK/PD) expected by year-end 2024.","Outstanding shares: 58,942,243 as of August 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":16146000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229286,"accession_number":"0000950170-24-072467","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pyxis Oncology stockholders elect four directors, ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Santhosh Palani elected Class I director with 28,241,400 for, 93,674 withheld.","Class III directors elected: John Flavin (21,045,395 for), Lara Sullivan (24,369,861), Jakob Dupont (28,220,452).","Ratification of Ernst & Young as FY2024 auditor passed with 42,153,375 for, 151,087 against, 31,729 abstain.","Quorum of 42,336,191 shares present from 58,876,390 outstanding as of record date April 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229285,"accession_number":"0001193125-24-157911","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology appoints Michael A. Metzger (CEO of Syndax) to board effective June 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael A. Metzger appointed to Pyxis Oncology Board as Class II director, effective June 10, 2024.","Metzger is CEO of Syndax Pharmaceuticals (Nasdaq: SNDX) and has over 25 years biopharma experience.","He will serve on Audit and Compensation Committees; received stock options for 70,683 shares vesting over three years.","Board determined Metzger qualifies as independent director under Nasdaq standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229284,"accession_number":"0000950170-24-059093","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q1 net loss narrows to $3.3M; PYX-201 data on track for fall 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $16.1M from Novartis royalty settlement; net loss $3.3M ($0.06/sh) vs $19.2M ($0.54/sh) YoY.","Cash & investments $158.5M; runway into 2H 2026; raised ~$60.8M via ATM, private placement, and Novartis deal.","PYX-201 Phase 1: 42 patients dosed; 16 more planned; results including efficacy expected fall 2024.","PYX-106 Phase 1: 24 subjects dosed; preliminary data anticipated in 2H 2024.","Appointed Stephen Worsley as Senior Vice President, Chief Business Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":16146000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247878,"accession_number":"0000950170-24-037176","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology files pro forma financials for Apexigen acquisition; combined net loss $97.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pro forma combined net loss for FY 2023: $97.8M (basic EPS $2.29).","Purchase price for Apexigen: $10.7M, comprising 4.3M Pyxis shares at $2.295/share.","Intangible assets acquired: $24.5M (IPR&D $21.0M, royalty rights $3.5M).","Nonrecurring transaction costs included: $1.7M in Pyxis G&A, $5.5M in Apexigen G&A.","Severance costs of $4.7M recorded: $1.6M G&A, $3.1M R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247877,"accession_number":"0000950170-24-036822","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology sells royalty rights to Novartis for $8M upfront cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-time $8M payment from Novartis for rights to Beovu and another asset royalties.","All prior royalties from Apexigen and Pyxis Oncology are free from reclaim.","Non-dilutive capital to support lead ADC asset PYX-201 development.","Pyxis retains rights to three other antibodies from Apexigen licensees.","$8M payment to be recorded in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247876,"accession_number":"0000950170-24-034427","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology reports FY2023 net loss of $73.8M, advances PYX-201 and PYX-106 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $73.8M ($1.85/share) vs $120.7M ($3.65/share) in FY2022; R&D expenses fell to $49.6M from $86.1M.","Cash, equivalents, and short-term investments $120.8M as of Dec 31, 2023; post-period raised $50M PIPE and $10.8M ATM, extending runway into 2H 2026.","PYX-201 Phase 1: 37 patients dosed; cleared DLT for Cohort 6; escalating to Cohort 7 at 8 mg/kg; initial data expected fall 2024.","PYX-106 Phase 1: 21 patients dosed; Cohort 5 fully enrolled at 8 mg/kg Q2W; preliminary data expected 2H 2024.","Feb 2024 PIPE investors include Deep Track Capital, Ridgeback, Blue Owl, Laurion Capital, StemPoint Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247875,"accession_number":"0000950170-24-030817","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology appoints Santhosh Palani, Ph.D., CFA to board; grant of 69,760 options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Santhosh Palani appointed to Pyxis Oncology board effective March 12, 2024.","Dr. Palani brings strategic and investment experience from PFM Health Sciences, NEA, and Cowen.","Received stock options for 69,760 shares at $5.70 exercise price, vesting over 3 years.","No committee assignments yet; independent director under Nasdaq standards.","Press release issued March 13, 2024 announcing the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}